MARKET COMPOSITE
AZYO - Aziyo Biologics Inc
Price
$0.00
+ 0.00 (0.00%)
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo, a biological envelope that remodels into vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic devices; and ProxiCor, Tyke, and VasCure, which are a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors, and proteins for use in vascular and cardiac repair, and pericardial closure. The company also provides FiberCel, ViBone, and OsterGro V that are viable matrices designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated human cellular dermal matrix designed to meet a range of surgical needs. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was founded in 2015 and is headquartered in Silver Spring, Maryland. It has additional offices in Roswell, Georgia; and Richmond, California
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue-4.7MM-177%
Gross Profit901K-68%
Cost Of Revenue-5.6MM-271%
Operating Income-7.7MM+4%
Operating Expenses8.6MM-16%
Net Income-9.3MM-4%
R&D868K+56%
G&A3.7MM+33%
Marketing1.3MM-53%
Interest Expense1.3MM-12%
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will participate on a panel at the Cantor Global Healthcare Conference. The panel discussion will take place in New York on Wednesday, September 27, 2023, at 8:00 am ET. A live webcast of the panel can be accessed by visiting the Company’s Events & Presentations webpage or b

    – Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it has entered into a securities purchase agreement for a private placement (PIPE) financing that is expected to result in initial gross proceeds to the Company of approximately $10.5 million, before deducting offering expenses. The full

    – Transaction Reflects Increasing Strategic Focus on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced the divestiture of the Company’s Orthobiologics business unit to Berkeley Biologics LLC, a wholly owned subsidiary of GNI Group Ltd. Elutia will receive cash proceeds of up to $35 million, comprised of an upfront payment at closing of $1

    SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET. A live webcast of the presentation can be accessed by visiting the Company’s Events & Presentations web

    Aziyo Biologics Inc., a Silver Spring biotech company that makes a range of medical devices to aid with implants, tissue repair, bone reconstruction and other procedures, is changing its name to Elutia Inc. The new name, which took effect Thursday, was chosen to reflect the company’s strategic focus on developing drug-eluting devices designed to minimize complications during surgeries. The rebranding comes ahead of the anticipated launch next year of its CanGaroo Envelope, a pouch that emits a...

    – Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company’s stock will begin trading on Nasdaq under the

    Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that dem

    Aziyo Biologics, Inc. (NASDAQ:AZYO) Q2 2023 Earnings Call Transcript August 20, 2023 Operator: Good day, ladies and gentlemen. Welcome to the Aziyo Biologics’ Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference call is being recorded. I would now like to hand the conference over to Matt Steinberg of […]

    Q2 2023 Aziyo Biologics Inc Earnings Call

    Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today